The Foods & Oil to Repair, Correct and Enhance Strength (FORCES) Study

NCT ID: NCT06361511

Last Updated: 2025-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

66 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-01

Study Completion Date

2030-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The proposed research is a parallel arm, randomized placebo-controlled clinical trial designed to assess changes in muscle strength, volume, fatigue resistance, and mobility in older adults after daily consumption of 12g of linoleic acid-rich oil.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Objectives

1. To assess the effect of linoleic acid supplementation on muscle strength, muscle volume, fatigue- resistance, and physical mobility.
2. To quantify the impact of linoleic acid supplementation on cardiolipin species and mitochondrial function in skeletal muscle of older adults

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

High Linoleic Safflower Oil

consumption of 12g of high linoleic safflower oil every day

Group Type EXPERIMENTAL

High Linoleic Acid Foods

Intervention Type OTHER

Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily

High Oleic Safflower Oil

Consumption of 12g of high oleic safflower oil every day

Group Type PLACEBO_COMPARATOR

High Oleic Acid Foods

Intervention Type OTHER

Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High Linoleic Acid Foods

Two food products containing 6g of high linoleic safflower oil each will be consumed each day for a total of 12g daily

Intervention Type OTHER

High Oleic Acid Foods

Two food products containing 6g of high oleic safflower oil each will be consumed each day for a total of 12g daily

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Linoleic Acid Intake \<75% of the adequate intake
* Probable sarcopenia

Exclusion Criteria

* Gastrointestinal diseases or disorders (including pancreatic and gastric bypass surgery) where consumption of the study foods would be contraindication or where the disease or disorder could negatively affect nutrient absorption and/or would prevent participants from tolerating the study foods
* Hyperthyroidism diagnosis
* Food Allergy or intolerances
* Any dietary restriction where consumption of the study foods or any ingredient would be contraindicated
* Unstable management of heart failure, heart disease events (including stroke or heart attack) within last 3 months prior to enrollment, a plan for heart surgeries or cardiac procedures
* Current or previous diagnosis of severe kidney failure, liver cirrhosis, other liver diseases/infections that cause liver damage and some pulmonary diseases or severe/uncontrolled pulmonary diseases
* Severe or uncontrolled rheumatologic or orthopedic diseases
* Current diagnosis of or current treatment of cancer other than non-melanoma skin cancer
* Neuromuscular or neurological conditions or diseases or use of mobility assistance (wheelchair, walker etc..) that would impact movement needed to perform the muscle function tests or prevent completion of the muscle function tests
* Use of mobility assistance (wheelchair, walker etc..) that would prevent completion of the muscle function tests
* Current use of supplements or medications for weight loss or following a weight loss program
* Use of supplements high in linoleic acid in the past 4 weeks prior to enrolling
* Pregnancy and lactation
* Alcohol or drug abuse
* Allergy/intolerance to lidocaine or similar medication
* Use of anticoagulant, antiplatelet, or other blood thinner medications
* Terminal Illness
* Any condition leading to muscle loss or weakness, impaired mobility or range of motion in legs (excluding normal aging)
Minimum Eligible Age

65 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institutes of Health (NIH)

NIH

Sponsor Role collaborator

Ohio State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Martha Belury

Professor and Chair, Food Science and Technology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martha Belury, PhD RDN

Role: PRINCIPAL_INVESTIGATOR

Ohio State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Ohio State University

Columbus, Ohio, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Martha Belury, PhD RDN

Role: CONTACT

614-292-1680

Rachel Cole

Role: CONTACT

614-247-8235

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Martha Belury, PhD

Role: primary

614-292-1680

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023H0284

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.